Trial Profile

A Phase 1 Clinical Formulation Selection Pharmacokinetic Study of TNX-601 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naloxone/tianeptine (Primary)
Indications Post-traumatic stress disorders
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

09 Nov 2021 According to a Tonix Pharmaceuticals Holding Corp media release, data from this study presented in a Poster Presentation at CNS Summit 2021
21 May 2020 According to a Tonix Pharmaceuticals Holding Corp media release, data from this trial will be presented at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting to be held online virtually on May 29-30, 2020.
16 Dec 2019 Results presented in a Tonix Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com